Acumen Pharmaceuticals, Inc. (ABOS)
USD 1.79
(-8.67%)
USD 1.79
(-8.67%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -43.06 Million | -35.15 Million | -17.96 Million | -7.45 Million | -6.81 Million |
| Net Income | -52.37 Million | -42.85 Million | -100.6 Million | -7.32 Million | -7.9 Million |
| Depreciation & Amortization | 184 Thousand | 169 Thousand | 4000.00 | - | - |
| Deferred income taxes | -6.77 Million | - | 155 Thousand | - | - |
| Stock-based compensation | 6.14 Million | 3.06 Million | 922 Thousand | 154 Thousand | 174 Thousand |
| Change in working capital | 3.86 Million | 3.98 Million | 298 Thousand | 307 Thousand | 768 Thousand |
| Other non-cash items | 5.88 Million | 487 Thousand | 81.26 Million | -586 Thousand | 147 Thousand |
| Investing Cash Flow | -171.67 Million | 39.18 Million | -104.12 Million | - | - |
| Investments in PPE | -21 Thousand | -161 Thousand | -40 Thousand | - | - |
| Acquisitions | 3000.00 | -39.34 Thousand | - | - | - |
| Investment purchases | -250.63 Million | -41.51 Million | -104.08 Million | - | - |
| Sales/Maturities of investments | 78.98 Million | 80.86 Million | - | - | - |
| Other Investing Activities | -171.65 Thousand | 39.34 Thousand | -104.08 Thousand | - | - |
| Financing Cash Flow | 151.75 Million | 3.9 Million | 200.46 Million | 44.67 Million | 6.23 Million |
| Debt repayment | -29.52 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 122.22 Million | 3.9 Million | 200.46 Million | 44.67 Million | 6.23 Million |
| Other Financing Activities | 59.04 Million | 3.9 Million | 200.46 Million | 44.67 Thousand | 6239.00 |
| Accounts receivables | - | - | - | -79 Thousand | 200 Thousand |
| Accounts payables | -261 Thousand | 552 Thousand | 557 Thousand | 308 Thousand | 110 Thousand |
| Inventory | - | - | - | 79 Thousand | -200 Thousand |
| Other working capital | 4.12 Million | 3.43 Million | -259 Thousand | -1000.00 | 658 Thousand |
| Cash at beginning of period | 130.1 Million | 122.16 Million | 43.77 Million | 6.55 Million | 7.13 Million |
| Cash at end of period | 66.88 Million | 130.1 Million | 122.16 Million | 43.77 Million | 6.55 Million |
| Capital Expenditure | -21 Thousand | -161 Thousand | -40 Thousand | - | - |
| Effect of forex changes on cash | -233 Thousand | - | - | - | - |
| Net cash flow / Change in cash | -63.21 Million | 7.93 Million | 78.38 Million | 37.22 Million | -579 Thousand |
| Free Cash Flow | -43.08 Million | -35.31 Million | -18 Million | -7.45 Million | -6.81 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -20.53 Million | -14.87 Million | -16.49 Million | -52.37 Million | -12.95 Million | -11.61 Million |
| Depreciation & Amortization | 45 Thousand | 44 Thousand | 39 Thousand | 184 Thousand | 40 Thousand | 53 Thousand |
| Deferred income taxes | - | - | -1.69 Million | -6.77 Million | 890 Thousand | 415 Thousand |
| Stock-based compensation | 2.47 Million | 2.48 Million | 1.63 Million | 6.14 Million | 1.6 Million | 1.52 Million |
| Change in working capital | 3.76 Million | -4.06 Million | 6.05 Million | 3.86 Million | -878 Thousand | -1.33 Million |
| Other non-cash items | -851 Thousand | -575 Thousand | 2.15 Million | 5.88 Million | -1.6 Million | -715 Thousand |
| Investing Cash Flow | 37.69 Million | -9.2 Million | -48.8 Million | -171.67 Million | -92 Million | 11.06 Million |
| Investments in PPE | -5000.00 | -11 Thousand | -14 Thousand | -21 Thousand | -7000.00 | - |
| Acquisitions | - | - | -3000.00 | 3000.00 | 3000.00 | - |
| Investment purchases | -11.8 Million | -45.29 Million | -71.77 Million | -250.63 Million | -126.72 Million | - |
| Sales/Maturities of investments | 49.5 Million | 36.1 Million | 22.98 Million | 78.98 Million | 34.72 Million | 11.06 Million |
| Other Investing Activities | 37.7 Million | -9.19 Million | -48.79 Thousand | -171.65 Thousand | -91.99 Thousand | 11.06 Thousand |
| Financing Cash Flow | -128 Thousand | 7.1 Million | 29.13 Million | 151.75 Million | 122.76 Million | -145 Thousand |
| Debt repayment | - | -739 Thousand | -29.52 Million | -29.52 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -32 Thousand | -390.00 | - | - | - |
| Common Stock Issuance | -128 Thousand | 7.87 Million | -390 Thousand | 122.22 Million | 122.76 Million | -145 Thousand |
| Other Financing Activities | -128 Thousand | -60 Thousand | 59.04 Million | 59.04 Million | 122.76 Thousand | -145.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.12 Million | 1.7 Million | 17 Thousand | -261 Thousand | -662 Thousand | 1.26 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.64 Million | -5.76 Million | 6.03 Million | 4.12 Million | -216 Thousand | -2.59 Million |
| Cash at beginning of period | 46.93 Million | 66.88 Million | 94.91 Million | 130.1 Million | 77.24 Million | 77.99 Million |
| Cash at end of period | 67.95 Million | 46.93 Million | 66.88 Million | 66.88 Million | 95.1 Million | 77.24 Million |
| Capital Expenditure | -5000.00 | -11 Thousand | -14 Thousand | -21 Thousand | -7000.00 | - |
| Effect of forex changes on cash | - | - | -44 Thousand | -233 Thousand | -16.25 Million | - |
| Net cash flow / Change in cash | 21.02 Million | -19.95 Million | -28.03 Million | -63.21 Million | 17.85 Million | -751 Thousand |
| Free Cash Flow | -16.55 Million | -17.87 Million | -8.32 Million | -43.08 Million | -12.91 Million | -11.67 Million |
SKS
CWY
BYD
CCZ
WEGYF
EGDD